Key Highlights
● Aldeyra intends to file a Formal Dispute Resolution Request with the FDA in the fourth quarter of 2026.
● The request would appeal the March 16, 2026 Complete Response Letter for reproxalap, an investigational treatment for dry eye disease.
● The company says it has data from nine adequate and well-controlled trials, of which five achieved all multiplicity-controlled primary endpoints.
● Cash and cash equivalents were $45.1 million as of June 30, 2026, and runway is now projected into 2029.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) filed a Form 8-K on September 29, 2026, saying it intends to file a Formal Dispute Resolution Request, or FDRR, with the U.S. Food and Drug Administration in the fourth quarter of 2026. The request would appeal the Complete Response Letter the agency issued on March 16, 2026 for reproxalap, the company's investigational treatment for dry eye disease. The company also said its projected cash runway now extends into 2029.
What the Filing Reports
The 8-K reports under three items. Item 7.01 (Regulation FD Disclosure) covers the company's recent Type D meeting with the FDA about reproxalap, held on September 25, 2026. Item 8.01 (Other Events) announces the intent to submit the FDRR. Item 9.01 lists two exhibits: Exhibit 99.1, a presentation dated September 29, 2026 that the company referenced during a conference call, and Exhibit 99.2, the press release of the same date.
The press release describes reproxalap as an investigational reactive aldehyde species, or RASP, modulator being developed for dry eye disease and allergic conjunctivitis. It says the decision to pursue the dispute process was informed by recent Type A and Type D meetings with the FDA's Division of Ophthalmology and Office of Specialty Medicine. The release does not describe the specific outcomes of the Type D meeting.
The Complete Response Letters
The release says Aldeyra has received three Complete Response Letters across its New Drug Application submissions. It states that the first two recommended an additional clinical trial to demonstrate a positive effect on the treatment of ocular symptoms of dry eye. The most recent letter, dated March 16, 2026, stated that the totality of evidence from the completed Clinical Trials does not support the effectiveness of the product.
Aldeyra's release points to its clinical program as the basis for disagreement, saying it has data from nine adequate and well-controlled clinical trials across its submissions, of which five achieved all multiplicity-controlled primary endpoints. These are the company's own characterizations.
How a Formal Dispute Request Works
According to the press release, the FDRR is expected to be submitted in the fourth quarter of 2026 and would be reviewed by the FDA's Office of New Drugs, with a meeting with that office also anticipated in the fourth quarter. The company adds that the timeline may extend if the agency requests additional information or convenes an advisory panel. The filing does not say what the FDA will decide, and it does not give a date for a decision.
Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, is quoted in the release as saying: "We remain steadfast in our commitment to working with the FDA to provide a novel therapeutic approach for the treatment of dry eye disease."
On financial condition, the release states that cash and cash equivalents were $45.1 million as of June 30, 2026, and that the company's operational cash runway is now projected to extend into 2029. The filing does not describe the assumptions behind that projection.
The company held a conference call at 8:00 a.m. ET on September 29, 2026, with a webcast available on its Investor relations website.
Aldeyra's Fourth-Quarter FDRR Timeline
The key event is the FDRR submission itself, which the company expects in the fourth quarter of 2026, followed by the anticipated meeting with the FDA's Office of New Drugs in the same quarter. The company has said the process could take longer if the agency asks for more information or convenes an advisory panel.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...